0001209191-22-001628.txt : 20220105
0001209191-22-001628.hdr.sgml : 20220105
20220105160430
ACCESSION NUMBER: 0001209191-22-001628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GEMAYEL GEORGES
CENTRAL INDEX KEY: 0001256088
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 22511091
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gemini Therapeutics, Inc. /DE
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (617) 401-4400
MAIL ADDRESS:
STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-03
0
0001816736
Gemini Therapeutics, Inc. /DE
GMTX
0001256088
GEMAYEL GEORGES
C/O GEMINI THERAPEUTICS, INC.
NOT APPLICABLE
DE
1
1
0
0
Executive Chair of the Board
Stock Option (Right to Buy)
3.08
2022-01-03
4
A
0
793274
0.00
A
2032-01-02
Common Stock
793274
793274
D
50% of the Option Shares shall become exercisable on August 5, 2022 and the remaining 50% of the Option Shares shall become exercisable on August 5, 2023.
/s/ Brian Piekos, attorney-in-fact
2022-01-05